3-(4-allyloxycarbonylbenzenesulfonyl)-1-(3,4-dimethylphenyl)-imidazolidine-2,4-dione | 177711-85-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-(4-allyloxycarbonylbenzenesulfonyl)-1-(3,4-dimethylphenyl)-imidazolidine-2,4-dione
• 英文别名: 3-(4-allyloxycarbonylbenzenesulfonyl)-1-(3,4-dimethylphenyl)-imidazolidin-2,4-dione；Prop-2-enyl 4-[3-(3,4-dimethylphenyl)-2,5-dioxoimidazolidin-1-yl]sulfonylbenzoate
• CAS: 177711-85-2
• 化学式: C₂₁H₂₀N₂O₆S
• 分子量: 428.466
• InChiKey: CEVNCRMHNIANNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  109
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(4-allyloxycarbonylbenzenesulfonyl)-1-(3,4-dimethylphenyl)-imidazolidine-2,4-dione 以54.5%的产率得到3-(4-carboxybenzenesulfonyl)-1-(3,4-dimethylphenyl)-imidazolidin-2,4-dione
  参考文献：
  名称：

  Imidazolidine derivative and use thereof

  摘要：

  该发明涉及一种由以下一般式（1）表示的咪唑啉衍生物：##STR1##其中A和B分别表示芳香烃基，该基可能被1-3个卤原子、C.sub.1-4烷基、C.sub.1-4烷氧基、C.sub.1-4烷二氧基、苯氧基、硝基、氰基、苯基、C.sub.2-5烷酰氨基、可能与C.sub.1-4烷基或烯基酯化的羧基、可能与C.sub.1-4烷基或烯基酯化的羧基烷基、可能与C.sub.1-4烷基或烯基酯化的羧基烷氧基、N-烷基哌嗪甲酰基、N-烷基哌嗪甲酰基烷基、N-烷基哌嗪甲酰基烷氧基和吗啉甲酰基；X表示磺酰基或羰基；Y代表氧原子或硫原子，包括作为活性成分的Ⅰ型肽酶抑制剂、以及作为活性成分的药物，其为一种心脏或循环系统疾病的预防和治疗剂，该疾病是由于抑制Ⅱ型肽酶的异常加速产生而引起的。

  公开号：

  US05691335A1

文献信息

• PREVENTIVES OR REMEDIES FOR EYE CIRCULATORY FAILURE
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP1112749A2

  公开（公告）日：2001-07-04

  The conventional pharmaootherapy for diseases caused by a disturbance of ocular circulation, inclusive of glaucoma, comprises oral administration of steroids and other drugs and/or topical administration of β -adrenergic antagonists but these therapeutic regimens are invariably not effective enough but rather entail adverse reactions characteristic of the respective drugs used. This invention is characterized in that a chymase inhibitor is used for the prevention or treatment of diseases caused by a disturbance of ocular circulation and enables positive prophylaxis or therapy with reduced risks for side effects.

  传统的药物疗法用于治疗眼循环障碍引起的疾病，包括青光眼，包括口服类固醇和其他药物和/或局部使用β-肾上腺素能拮抗剂，但这些治疗方案总是不够有效，反而会引起所用药物特有的不良反应。 本发明的特点在于，糜蛋白酶抑制剂可用于预防或治疗由眼部循环障碍引起的疾病，并能在降低副作用风险的同时进行积极的预防或治疗。
• TENSION-RELIEVING AGENTS FOR CILIARY MUSCLE
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：EP1224945A1

  公开（公告）日：2002-07-24

  Use of a chymase inhibitor in preventing and treating nearsightedness caused by the continuous tension of ciliary muscles makes it possible to achieve exact preventive and therapeutic effects with little side effects.

  使用糜蛋白酶抑制剂来预防和治疗因睫状肌持续紧张而引起的近视，可以达到确切的预防和治疗效果，而且副作用很小。
• Prophylactic or threapeutic composition for ocular circulation disorders
  申请人：——

  公开号：US20040086537A1

  公开（公告）日：2004-05-06

  The conventional pharmacotherapy for diseases caused by a disturbance of ocular circulation, inclusive of glaucoma, comprises oral administration of steroids and other drugs and/or topical administration of &bgr;-adrenergic antagonists but these therapeutic regimens are invariably not effective enough but rather entail adverse reactions characteristic of the respective drugs used. This invention is characterized in that a chymase inhibitor is used for the prevention or treatment of diseases caused by a disturbance of ocular circulation and enables positive prophylaxis or therapy with reduced risks for side effects.

  对眼部循环障碍引起的疾病（包括青光眼）的传统药物治疗包括口服类固醇和其他药物和/或局部使用肾上腺素能拮抗剂，但这些治疗方案总是不够有效，反而会引起所用药物特有的不良反应。 本发明的特点在于，糜蛋白酶抑制剂可用于预防或治疗由眼部循环障碍引起的疾病，并能在降低副作用风险的情况下进行积极的预防或治疗。
• IMIDAZOLIDINE DERIVATIVE AND USE THEREOF
  申请人：SUNTORY LIMITED

  公开号：EP0721944B1

  公开（公告）日：2001-01-17
• Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders
  申请人：Talley John Jeffrey

  公开号：US20090054319A1

  公开（公告）日：2009-02-26

  The use of guanylin potentiating agents for treating various disorders, including hypertension as well as IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, duodenogastric reflux, dyspepsia, functional dyspepsia, nonulcer dyspepsia, a functional gastrointestinal disorder, functional heartburn, gastroesophageal reflux disease (GERD), gastroparesis, inflammatory bowel disease, irritable bowel syndrome, post-operative ileus, ulcerative colitis, chronic constipation, and disorders and conditions associated with constipation is described.